Siddharth S. Bass
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Siddharth S. Bass.
Annals of Surgical Oncology | 1999
Charles E. Cox; Siddharth S. Bass; David Boulware; NiNi K. Ku; Claudia Berman; Douglas S. Reintgen
Background: Recent advances in technology and the subsequent development of minimally invasive surgical techniques have heralded a new era in the surgical treatment of breast cancer. The dilemma of how to train surgeons in new technologies requires teaching, certification, and outcomes reporting in a non-threatening and non–economically damaging manner. This study examines 700 cases of lymphatic mapping and sentinel lymph node (SLN) biopsy for breast cancer and documents surgeon-specific and institution-specific learning curves.Methods: Seven hundred cases of lymphatic mapping and SLN biopsy were examined. All procedures were performed using a combination of vital blue dye and radiolabeled sulfur colloid. Learning curves were generated for each surgeon as a plot of failure rate versus number of cases.Results: Examination of the learning curves in this study demonstrates similar characteristics. Following a high initial failure rate, there is a rapid decrease after the first twenty cases. The learning curve, representing the mean of the five surgeons’ experience, indicates that 23 cases and 53 cases are required to achieve success rates of 90% and 95%, respectively.Conclusions: The initial reports regarding lymphatic mapping combined with this experience of 700 cases confirm the presence of a significant learning curve. Although this procedure may have an inherent failure rate, it is important to identify those factors that are under the control of the surgeon and, therefore, subject to improvement. We believe that these data provide surgeons performing lymphatic mapping and SLN biopsy with a new paradigm for assessing their skill and adequacy of training.
Breast Journal | 1999
Siddharth S. Bass; Gary H. Lyman; Christa R. McCann; Ni Ni Ku; Claudia Berman; Kara Durand; Monica Bolano; Sarah Cox; Christopher Salud; Douglas S. Reintgen; Charles E. Cox
▪ Abstract: The status of the regional nodal basin remains the most important prognostic indicator of survival. The current standard of care for the management of invasive breast cancer is the complete removal of the tumor, with documentation of negative margins by either mastectomy or lumpectomy, followed by complete axillary lymph node dissection. Data suggest that complete lymph node dissection (CLND) provides better local control of the disease and may actually offer a survival advantage. Lymphatic mapping and sentinel lymph node (SLN) biopsy are clearly changing this long‐held paradigm and have the potential to change the standard of surgical care of the breast cancer patient. The purpose of this report is to describe the lymphatic mapping experience at the H. Lee Moffitt Cancer Center and Research Institute. From April 1994 to January 1999, 1,147 consecutive breast cancer patients were enrolled in an institutional review board‐approved lymphatic mapping protocol. Lymphatic mapping was performed using Tc99m‐labeled sulfur colloid and isosulfan blue dye. An SLN was defined as any blue node and/or any hot node with ex vivo radioactivity counts 10 times an excised non‐SLN or in situ radioactivity counts 3 times the background counts. Lymphatic mapping was successful in identifying the SLN in 1,098 of 1,147 (95.7%) cases. In the first 186 patients, all of whom underwent CLND following SLN biopsy, one false‐negative biopsy was encountered for a false‐negative rate of 0.83%. The method of diagnosis (excisional versus minimally invasive) does not appear to impact on lymphatic mapping. Tumor size, however, is directly related to the probability of axillary lymph node involvement. Advances in technology and the development of minimally invasive surgical techniques have heralded a new era in surgery. Lymphatic mapping and SLN biopsy may actually prove to be a more accurate method of identifying metastases to the axilla by allowing a more focused pathologic examination of the axillary node(s) at highest risk for metastasis. With adequate training, this technique can be readily implemented as a valuable tool in the surgical treatment of breast cancer. ▪
Journal of The American College of Surgeons | 2001
Siddharth S. Bass; Charles E. Cox; Christopher Salud; Gary H. Lyman; Christa R. McCann; Elizabeth Dupont; Claudia Berman; Douglas S. Reintgen
BACKGROUND The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy is rapidly becoming the preferred method of staging the axilla of the breast cancer patient. This report describes the impact of postinjection massage on the sensitivity of this surgical technique. STUDY DESIGN Lymphatic mapping at the H Lee Moffitt Cancer Center is performed using a combination of isosulfan blue dye and Tc99m labeled sulfur colloid. Data describing the rate of SLN identification and the node characteristics from 594 consecutive patients were calculated. Patients who received a 5-minute massage after injection of blue dye and radiocolloid were compared with a control group in which the patients did not receive a postinjection massage. RESULTS When compared with controls, the proportion of patients who had their SLN identified using blue dye after massage increased from 73.0% to 88.3%, and the proportion of patients who had their SLN identified using radiocolloid after massage increased from 81.7% to 91.3%. The overall rate of SLN identification increased from 93.5% to 97.8%. The proportion of nodes that were stained blue among those removed increased from 73.4% to 79.7% after massage. CONCLUSIONS As experience increases with this new procedure, the surgical technique of lymphatic mapping continues to evolve. The addition of a postinjection massage significantly improves the uptake of blue dye by SLNs and may also aid in the accumulation of radioactivity in the SLNs, further increasing the sensitivity of this procedure.
Journal of The American College of Surgeons | 1999
Siddharth S. Bass; Charles E. Cox; Ni Ni Ku; Claudia Berman; Douglas S. Reintgen
Journal of The American College of Surgeons | 1999
Siddharth S. Bass; Charles E. Cox; Ni Ni Ku; Claudia Berman; Douglas S. Reintgen
Annual Review of Medicine | 2000
Charles E. Cox; Siddharth S. Bass; Christa R. McCann; Ni Ni K. Ku; Claudia Berman; Kara Durand; Monica Bolano; Jessica Wang; Eric S. Peltz; Sarah Cox; Christopher Salud; Douglas S. Reintgen; Gary H. Lyman
Oncology | 1998
Charles E. Cox; Fadi Haddad; Siddharth S. Bass; John M. Cox; Ni Ni Ku; Claudia Berman; Alan R. Shons; Timothy J. Yeatman; Solange Pendas; Douglas S. Reintgen
Surgical Oncology Clinics of North America | 1999
Siddharth S. Bass; Charles E. Cox; Douglas S. Reintgen
Surgical Oncology Clinics of North America | 1999
Charles E. Cox; Siddharth S. Bass; Douglas S. Reintgen
Recent results in cancer research | 1998
Charles E. Cox; Siddharth S. Bass; N. N. K. Ku; Claudia Berman; Alan R. Shons; Timothy J. Yeatman; Douglas S. Reintgen